The broad, long-term objective of this proposal for a cooperative drug discovery group is to meet the critical and urgent need for discovery of more effective and less toxic drugs and regimens for treatment of toxoplasmosis in AIDS patients. Toxoplasmosis has emerged as a major cause of morbidity in patients with AIDS. Drugs that have proven effective in treatment of toxoplasmosis in AIDS are extremely limited and those most commonly used are frequently associated with drug reactions sufficiently severe to preclude their further use in a given patient. Thus, there is a real need to discover and evaluate new treatment modalities for toxoplasmosis in AIDS patients.
The specific aims of Project 1 are: a) to evaluate newer therapeutic agents/combinations for their activity against tachyzoites of T. gondii in vitro and in vivo. Mammalian cells in tissue culture and murine models of toxoplasmic encephalitis will be used in these studies; b) to use a newly developed technology to study therapeutic agents against the tissue cyst form and bradyzoites of T. gondii in vitro and in vivo. For this purpose mice with chronic central nervous system infection will be treated as well as cysts isolated from brains of chronically infected mice; c) to investigate the therapeutic potential of agents for toxoplasmosis. These studies will be performed in vitro in tissue culture as well as in in vivo in a model of systemic toxoplasmosis and models of toxoplasmic encephalitis; d) to examine drug-drug interactions of the effect of drugs being used to treat HIV infection on the in vitro and in vivo anti- toxoplasma effects of drugs being studied for treatment to toxoplasmosis in AIDS patients.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Palo Alto Medical Foundation Research Institute
Department
Type
DUNS #
622276137
City
Palo Alto
State
CA
Country
United States
Zip Code
94301
Saeij, J P J; Boyle, J P; Coller, S et al. (2006) Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 314:1780-3
McFadden, D C; Tomavo, S; Berry, E A et al. (2000) Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 108:12-Jan
Liesenfeld, O; Kang, H; Park, D et al. (1999) TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol 21:365-76
McFadden, D C; Boothroyd, J C (1999) Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii. J Eukaryot Microbiol 46:81S-82S
Boothroyd, J C; Hehl, A; Knoll, L J et al. (1998) The surface of Toxoplasma: more and less. Int J Parasitol 28:3-9
Black, M W; Boothroyd, J C (1998) Development of a stable episomal shuttle vector for Toxoplasma gondii. J Biol Chem 273:3972-9
Neyer, L E; Kang, H; Remington, J S et al. (1998) Mesenteric lymph node T cells but not splenic T cells maintain their proliferative response to concanavalin-A following peroral infection with Toxoplasma gondii. Parasite Immunol 20:573-81
Manger, I D; Hehl, A B; Boothroyd, J C (1998) The surface of Toxoplasma tachyzoites is dominated by a family of glycosylphosphatidylinositol-anchored antigens related to SAG1. Infect Immun 66:2237-44
Manger, I D; Hehl, A; Parmley, S et al. (1998) Expressed sequence tag analysis of the bradyzoite stage of Toxoplasma gondii: identification of developmentally regulated genes. Infect Immun 66:1632-7
Subauste, C S; Fuh, F; de Waal Malefyt, R et al. (1998) Alpha beta T cell response to Toxoplasma gondii in previously unexposed individuals. J Immunol 160:3403-11

Showing the most recent 10 out of 55 publications